PARIS, FRANCE / ACCESSWIRE / October 19, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative
Investegate announcements from Pharnext, Pharnext strengthens its management team with three key appointments to support ongoing development of PXT3003 toward approval and commercialization
Pharnext Reports Financial Results for Year-End -2-
DJ Pharnext Reports Financial Results for Year-End 2020
Pharnext
Pharnext Reports Financial Results for Year-End 2020
27-Apr-2021 / 19:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Pharnext Reports Financial Results for Year-End 2020
PARIS, France, April 27, 2021, 7:00 p.m. CET - Pharnext SA (FR0011191287 - ALPHA) (the Company ), an advanced
late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations
based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, today announces its
financial results for the fiscal year ended December 31, 2020.